Pixyl, Brainomix Partner on MRI Software to Help Diagnosis of MS |...
Summary
According to the partners, Pixyl‘s technology can detect abnormalities on magnetic resonance imaging or MRI scans in fewer than five minutes — potentially speeding the diagnosis of MS and other neurological diseases. Under the new partnership, the company will leverage its customer base and sales force to distribute Pixyl’s Neuro.MS Software as a Service (SaaS) solution in the United Kingdom and Ireland, the Nordic countries, and key markets across Eastern Europe. “We recognized that there was an opportunity to form these types of third-party technology partnerships, as a way of offering our customers a broader set of AI-enabled solutions,” Michalis Papadakis, PhD, Brainomix cofounder and CEO, said in a company press release. “We are excited to embark on this partnership with Pixyl — a company with whom we share a common vision focused on developing innovative, AI-powered solutions that can enhance diagnostic and treatment decisions,” Papadakis said. “Leveraging Brainomix’s large installed base and dedicated sales force in some of Europe’s leading markets represents a strategic step in our vision to broaden the adoption of AI-powered, clinically relevant solutions to drive better patient outcomes in the neurology imaging space,” said Senan Doyle, PhD, Pixyl’s co-founder and CEO.